Biosimilars

A Global Strategic Business Report

MCP-6201

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

10129

EXECUTIVE POOL

5850

PRICE

1213

EXPERT INPUTS

46

COMPANIES

122

DATA TABLES

193

PAGES

18

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (27040)

617

CXO

1669

VICE PRESIDENT

12604

DIRECTOR

8921

MANAGER

3229

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Biosimilars Market to Reach US$135.9 Billion by 2030

The global market for Biosimilars estimated at US$45.5 Billion in the year 2024, is expected to reach US$135.9 Billion by 2030, growing at a CAGR of 20.0% over the analysis period 2024-2030. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$62.4 Billion by the end of the analysis period. Growth in the Recombinant Glycosylated Proteins segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.2 Billion While China is Forecast to Grow at 19.5% CAGR

The Biosimilars market in the U.S. is estimated at US$13.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$21.1 Billion by the year 2030 trailing a CAGR of 19.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.7% and 16.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.

Biosimilars - Key Trends and Drivers

Biosimilars are biologic medical products that are highly similar to already approved reference biologics, with no significant differences in terms of safety, purity, and potency. These products are derived from living organisms, making their production and development significantly more complex than traditional small-molecule drugs. Biosimilars are used to treat a range of diseases, including cancers, autoimmune disorders, and chronic conditions like diabetes and rheumatoid arthritis. The development of biosimilars involves a rigorous process of demonstrating similarity to the reference product through comprehensive analytical studies, non-clinical assessments, and clinical trials. This ensures that biosimilars can effectively replace their more expensive counterparts, providing significant cost savings for healthcare systems and increasing patient access to critical treatments. The process includes demonstrating that the biosimilar has the same mechanism of action, route of administration, dosage form, and strength as the original biologic, ensuring that it delivers the same clinical benefits.

The biosimilars market has witnessed substantial growth and transformation over the past decade. Regulatory frameworks in major markets such as the United States, Europe, and Asia have evolved to support the approval and adoption of biosimilars. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have established robust guidelines that streamline the approval process, fostering confidence among healthcare providers and patients. These guidelines require comprehensive comparative studies that confirm the biosimilar’s similarity to the reference biologic without clinically meaningful differences. Additionally, the patent expirations of several blockbuster biologics have opened the door for biosimilar competition. Pharmaceutical companies are investing heavily in the development and commercialization of biosimilars, leveraging advanced manufacturing technologies to ensure consistent quality and supply. This includes state-of-the-art cell culture processes, purification techniques, and stringent quality control measures. Collaborations and partnerships between biosimilar manufacturers and healthcare providers are also playing a critical role in expanding the market reach and acceptance of these products.

The growth in the biosimilars market is driven by several factors. Advances in biotechnology and manufacturing processes have enhanced the production efficiency and quality of biosimilars, making them more competitive with their reference biologics. The increasing prevalence of chronic diseases and the rising demand for cost-effective treatments are expanding the addressable market for biosimilars. For instance, as the incidence of conditions like cancer, diabetes, and autoimmune diseases continues to rise, so does the need for affordable treatment options. Healthcare cost containment measures and favorable reimbursement policies in various countries are also propelling the adoption of biosimilars. Governments and insurance providers are increasingly recognizing the potential of biosimilars to reduce healthcare expenditures, leading to supportive policies and incentives. Moreover, the growing acceptance of biosimilars among healthcare professionals and patients, driven by successful clinical outcomes and real-world evidence, is accelerating market growth. Strategic initiatives by pharmaceutical companies, such as expanding biosimilar portfolios and entering emerging markets, are further fueling the market`s expansion. These companies are also investing in extensive educational campaigns to build trust and acceptance among prescribers and patients. Additionally, efforts to educate stakeholders about the benefits and safety of biosimilars are enhancing their market penetration, ensuring that these life-saving therapies reach a broader patient population. As a result, biosimilars are poised to play an increasingly important role in global healthcare, offering high-quality, affordable alternatives to costly biologic therapies.

SCOPE OF STUDY

The report analyzes the Biosimilars market by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides); Disease (Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases, Other Diseases).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

Allergan Plc; Amgen Inc.; Biocon Ltd.; Biopartners GmbH; Boehringer Ingelheim International GmbH; Celltrion Inc.; Dr. Reddy`s Laboratories Ltd.; Eli Lilly and Company; Fresenius Kabi; Intas Pharmaceuticals Ltd.; Mylan NV; Pfizer Inc.; Samsung Bioepis Co. Ltd.; Sandoz International GmbH; STADA Arzneimittel AG; Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

Global Economic Update

Biosimilars – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 46 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Advances in Biotechnology Propel Growth in Biosimilars Market

Patent Expirations of Blockbuster Biologics Expand Addressable Market Opportunity for Biosimilars

Increasing Prevalence of Chronic Diseases Drives Demand for Cost-Effective Biosimilars

Regulatory Frameworks and Approvals Strengthen Business Case for Biosimilar Development

Growing Acceptance and Adoption of Biosimilars by Healthcare Providers Spur Market Growth

Technological Innovations in Manufacturing Processes Enhance Quality and Efficiency of Biosimilars

Real-World Evidence and Clinical Outcomes Drive Confidence and Demand for Biosimilars

Strategic Expansion into Emerging Markets Expands Global Reach of Biosimilars

Increasing Focus on Personalized Medicine Generates Demand for Specialized Biosimilars

Marketing Strategies Highlighting Cost and Clinical Benefits Drive Adoption of Biosimilars

Innovations in Cell Culture and Purification Techniques Strengthen Production of High-Quality Biosimilars

Growing Interest in Sustainable Manufacturing Practices Creates Opportunities in Biosimilar Production

Integration of Advanced Analytics and Big Data in Biosimilar Development Optimizes R&D Efforts

Rise in Investment and Funding for Biosimilar Research and Development Fuels Market Growth

Innovations in Biosimilar Delivery Mechanisms Generate Demand for User-Friendly Products

4. GLOBAL MARKET PERSPECTIVE

World Biosimilars Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Recombinant Non-glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Recombinant Glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Recombinant Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Recombinant Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Blood Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Blood Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Chronic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Chronic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

USA Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

Canada Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

JAPAN

Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

Japan Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

CHINA

Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

China Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

EUROPE

Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe 6-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030

Europe Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

Europe Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

FRANCE

Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

France Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

GERMANY

Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

Germany Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

Italy Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

UNITED KINGDOM

Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

UK Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

ASIA-PACIFIC

Biosimilars Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World 6-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2025 & 2030

Rest of World Recent Past, Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World 6-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
3SBio, Inc.	%
4care Company Limited	%
Abbexa	%
Accord-UK Ltd.	%
Advanz Pharma Corp Ltd.	%
Alteogen, Inc.	%
Alvogen	%
Alvotech	%
Apotex, Inc.	%
Aprogen	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll